drugset / Trial / NCT01879657
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Completed
169 enrolled
Radio Isotope Therapy of America
Excel Diagnostics and Nuclear Oncology Center · collabRadiomedix, Inc. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers and other imaging modalities like CT scan/MRI as gold standard.
Timeline
- Start
- 2013-03-01
- Primary completion
- 2015-12-30
- Completion
- 2017-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATATE | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-DOTATATE | Diagnostic / imaging agent | 185 mbq | Intravenous |